<DOC>
	<DOC>NCT01693471</DOC>
	<brief_summary>The objectives of this study are to investigate the influence on HR-QOL (SF-36 v2) resulting from the compliance of MUCODYNE Tablets or MUCODYNE DS (Dry Syrup) 50% in asthma patients whose control levels are partly controlled or uncontrolled.</brief_summary>
	<brief_title>Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients</brief_title>
	<detailed_description>Period: 2012-2013 Observation Time: 0 week, 4 week Matters investigated: 1. QOL determination using SF-36 v2 2. Medication compliance (VAS scale) 3. Gender, age, diagnosis, asthma subtype, severity, duration of disease, level of asthma control, concomitant drugs, comorbidities, smoking, alcohol, work</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Carbocysteine</mesh_term>
	<criteria>Male and female patients â‰¥ 20 years of age Outpatients Patients with mild or moderate persistent asthma Patients with phlegm Patients whose levels of asthma control are partly controlled or uncontrolled Patients who are planned to treat MUCODYNE Patients who voluntarily submitted written consent forms upon participation in this study Patients with a history of adverse reactions to carbocisteine Patients with serious cardiac, hepatic, renal, pulmonary, or hematological disease Patients with the possibility of pregnancy or suspected pregnancy Patients with complication of malignancy Current smoker Patients with definitive diagnosis for COPD Other patients whom investigators or subinvestigators considered inappropriate to participate in this study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>SF-36</keyword>
	<keyword>HRQOL</keyword>
</DOC>